Vigabatrin was approved for the treatment of infantile spasms by the US Food and Drug Administration, but not in Japan at the time of initiating this clinical study because of concerns about irreversible peripheral visual field defects (VFDs). This study evaluated the efficacy and safety of vigabatrin for Japanese patients with infantile spasms. Of 15 patients (aged ≥4 weeks and b 2 years) enrolled, with the exception of two patients who did not receive vigabatrin, 13 were treated with a titrated dosage of vigabatrin (50-150 mg/kg/day; limited to 3000 mg/day). Twelve out of 13 patients receiving vigabatrin had spasms that were treatment refractory; these patients were concurrently treated with at least one other antiepileptic drug. One patient received vigabatrin monotherapy. Eight of the 13 patients (61.5% [95% CI: 31.6-86.1%]) had a ≥ 50% reduction during the dose-adjustment phase compared with baseline in the frequency of spasms, with efficacy maintained through a 2-week maintenance phase. Spasms disappeared in six out of nine patients (66.7% [95% CI: 29.9-92.5%]) who transitioned to the maintenance phase and hypsarrhythmia on electroencephalography also resolved in four patients. Hypsarrhythmia was improved in another two patients. Six out of seven patients who continued treatment through Week 32 of an extension study reported ongoing efficacy for vigabatrin. The most common adverse events (AEs) were psychiatric disorders and nervous system disorders (n = 8; 61.5%) that were generally mild in severity. No treatment-related peripheral VFDs were observed. No severe AEs or AEs resulting in discontinuation of vigabatrin therapy were reported. An abnormality in magnetic resonance images was observed in one patient during the extension period. Vigabatrin was deemed to be clinically effective and well tolerated in Japanese patients with infantile spasms.
Introduction
Infantile spasms, or West syndrome, is classified as an "epileptic encephalopathy" by the International League Against Epilepsy (ILAE) Classification system [1] and is characterized by spasms, neurodevelopmental regression, and hypsarrhythmia on electroencephalography (EEG) in children mainly under the age of 2 years old [2] . Infantile spasms can be caused by a variety of underlying pathologies, including pre-, peri-, and postnatal brain insults; but a significant number of cases have an unknown etiology [3] . In most cases, the long-term developmental and seizure outcomes are devastating.
Currently approved treatments for infantile spasms in Japan include synthetic adrenocorticotrophic hormone (ACTH). Adrenocorticotrophic hormone is considered to be the most effective treatment for infantile spasms in Japan, but a high proportion (N 40%) of Japanese patients had spasms that relapsed after discontinuing treatment [4] . Treatment is also associated with a high risk of adverse events (AEs), including potentially life-threatening serious AEs (SAEs) [5] , so a short-duration/ low-dose ACTH regimen is often used in Japan to reduce the risk of SAEs [6] . Meanwhile, other treatment options are urgently required.
Vigabatrin has been well evaluated for the treatment of infantile spasms in many countries, especially in Europe [7, 8] , and is considered to be particularly efficacious in patients with tuberous sclerosis [9, 10] . It is a structural analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) that functions as a long-acting anticonvulsant by irreversibly binding GABA-transaminase, the primary GABA-degrading enzyme, increasing GABA levels in the brain [11] .
However, an increased risk of peripheral visual field defects (VFDs) following prolonged administration of vigabatrin (N12 months) has been reported in both adult and pediatric patients [10] . It has been suggested that vigabatrin-related peripheral VFDs are a result of vigabatrin inhibiting taurine uptake in the gastrointestinal tract, leading to taurine Epilepsy & Behavior 78 (2018) 
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